A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain



Status:Archived
Conditions:Skin Cancer, Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:February 2011
End Date:December 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain


The present study is designed to assess the efficacy, pharmacokinetics, safety, and
tolerability of an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with
BRAF V600E or V600K mutation-positive metastatic melanoma to the brain. Subjects in Cohort
A will not have received any local brain therapy and subjects in Cohort B will have received
prior local therapy for brain metastases. Subjects will continue on treatment until disease
progression, death, or unacceptable adverse event.



We found this trial at
4
sites
West Virginia University Hospitals Inc.
1 Medical Center Drive
Morgantown, West Virginia 26506
304-598-4800
West Virginia University Hospitals Inc. WVU Healthcare is two corporations, University Health Associates and WVU...
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
GSK Investigational Site
Anaheim, California 92807
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
GSK Investigational Site
Kennewick, Washington 99336
?
mi
from
Kennewick, WA
Click here to add this to my saved trials
GSK Investigational Site
Knoxville, Tennessee 37916
?
mi
from
Knoxville, TN
Click here to add this to my saved trials